Navigation Links
LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

Company's Form 10-K report for the year ended December 31, 2007. This release also contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as the Company's outlook for 2008 operating results. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward- looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. These forward- looking statements may not be realized due to a variety of factors, including, without limitation: the failure to maintain or increase revenues from the sale of our AlloDerm products; the failure to comply with government regulations, including the FDA; product recalls; claims for damages by third-parties, including product liability claims; our dependence on a limited number of sources for human cadaveric tissue; negative publicity about the use of donated human tissue in medical procedures; our ability to increase market penetration of our current products and to develop and commercialize new products; changes in third party reimbursement practices; the failure of independent sales and marketing agents and distributors to adequately promote, market and distribute our products; our inability to protect our intellectual property; the effects of competition; and the other factors listed under "Risk Factors" in our annual report on Form 10-K and our other filings with the Securities and Exchange Commission. The Company assumes no obligation to update the information contained in th
'/>"/>
SOURCE LifeCell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
2. AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance
3. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
4. Claimsnet.com Reports Fiscal Year 2007 Results
5. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
6. Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results
7. 012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007
8. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007
9. NHP Reports Fourth Quarter and Full Year 2007 Earnings
10. High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter
11. Clarity for Consumers on Botox Complication and Death Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... flow and alleviates muscle soreness after exercise, according ... of Illinois at Chicago. , The study, reported ... Archives of Physical Medicine and Rehabilitation , also ... who had not exercised, suggesting that massage has ... physical activity. , Improved circulation and relief of ...
(Date:4/17/2014)... TORONTO, April 17, 2014While 94 per cent of Canadians ... that screen newborns for a specific number of genetic ... willing to participate in screening that would sequence their ... prick test" in their first day or two of ... taken from their heels and tested for about five ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Pa., June 1 Practice-Reps, LLC ( http://www.practice-reps.com ) ... to specialty medical practices along the East Coast. The ... a 16-year veteran of the practice marketing industry, to ... experienced marketing support on a part-time basis. , ...
... SAN FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. ... oral Syk inhibitor, R788, is being evaluated in a ... the National Cancer Institute (NCI), part of the U.S. ... trial will include patients with advanced colorectal, thyroid, non-small ...
... , Collaboration Delivers Cost and Quality Benefits for Widespread ... June 1 SAFC(R) ( www.safcglobal.com ), a member ... and Cherokee Pharmaceuticals(TM) ( www.cherokee-pharma.com ... business, today announced an exclusive strategic partnership that encompasses ...
... , New Product Names for Recently Introduced MicroRNA-based Diagnostics ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... platform yesterday at the American Society of Clinical Oncology ... a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) ...
... the mouth and periodontists to ask questions about heart health ... leading killer of men and women in the United States, ... each day. Periodontal disease, a chronic inflammatory disease that destroys ... 75 percent of Americans and is the major cause of ...
... program aimed at reducing criminal behavior in juvenile justice teens ... reducing the teens, rate of pregnancy, according to a new ... in the Department of Psychology at Oregon State University, and ... Learning Center, conducted the research, which will be published in ...
Cached Medicine News:Health News:Practice-Reps Brings Sales and Marketing to the Business of Medical Practice Management 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 2Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 3Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4Health News:Intervention reduces delinquent teenage pregancy rates 2Health News:Intervention reduces delinquent teenage pregancy rates 3
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... WellPoint, Inc. (NYSE: WLP ) is the first ... guidelines that it will use when evaluating drugs for purposes of ... plans. , , , ... guidelines in the public domain, we are providing some guidance to pharmaceutical ...
... PFE ) invites investors and the general public to view and listen to a ... at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010 , at ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO ... To view and listen to the webcast, ...
Cached Medicine Technology:WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 2WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 3WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 4Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Inquire...
Medicine Products: